Figure S1. EPO and plasma chemokine expression following treatment with ARRY-614 at 1200 mg QD. EPO, MCP-4 and MIP-1 $\beta$  were measured using a quantitative, multiplex assay as described in the Methods. Data are represented as the mean% of Baseline with error bars indicating standard error of the mean (SEM). Symbols represent changes in analytes from Baseline following ARRY-614 treatment: EPO (n=16,  $\bullet$ ), MCP-4 (n=16,  $\cdot$ ), and MIP-1 $\beta$  (n=16,  $\diamond$ ).

Figure S2. Comparison of EPO in IWG2006 Responders and Non-Responders. EPO was measured using a quantitative multiplex assay as described in the Methods. Data are represented as the mean% of Baseline with error bars indicating standard error of the mean (SEM). Symbols represent changes in plasma EPO concentrations from Baseline following treatment with ARRY-614 for IWG2006 Responders and Non-Responders: Responders (n=14, ●) and Non-Responders (n=30, □).

Figure S1




Figure S2

